Novel pathogenic FOXP3 variant in two unrelated families with IPEX syndrome
Journal of Human Immunity · 2027-01-04 · 3 (1)
DOI: 10.70962/jhi.20250036 ↗Abstract
The authors describe three patients with IPEX due to a novel pathogenic variant, two of which have been successfully treated with stem cell transplant. Confidence about variant pathogenicity is difficult in IPEX, and hematopoietic stem cell transplantation (HSCT) outcomes are variable; reporting classical IPEX due to novel variants, in this case with an elevated TSDR, remains essential.
EUVIMED